Wedbush Issues Optimistic Estimate for BDTX Earnings

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) – Investment analysts at Wedbush boosted their Q2 2025 EPS estimates for shares of Black Diamond Therapeutics in a research report issued to clients and investors on Tuesday, May 13th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings of ($0.25) per share for the quarter, up from their prior forecast of ($0.28). Wedbush currently has a “Outperform” rating and a $11.00 target price on the stock. The consensus estimate for Black Diamond Therapeutics’ current full-year earnings is ($1.30) per share. Wedbush also issued estimates for Black Diamond Therapeutics’ Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at $0.27 EPS, FY2026 earnings at ($0.80) EPS, FY2027 earnings at ($0.77) EPS, FY2028 earnings at ($0.66) EPS and FY2029 earnings at $0.39 EPS.

Black Diamond Therapeutics (NASDAQ:BDTX) last issued its quarterly earnings data on Thursday, March 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.03.

Several other research firms also recently weighed in on BDTX. HC Wainwright boosted their target price on shares of Black Diamond Therapeutics from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, March 18th. Stifel Nicolaus lowered their price target on shares of Black Diamond Therapeutics from $16.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, March 7th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Black Diamond Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $14.60.

Black Diamond Therapeutics Trading Up 1.0%

NASDAQ:BDTX opened at $1.95 on Friday. The company has a market cap of $110.52 million, a PE ratio of -1.47 and a beta of 2.63. Black Diamond Therapeutics has a twelve month low of $1.20 and a twelve month high of $6.75. The company’s 50 day moving average is $1.60 and its two-hundred day moving average is $2.12.

Insider Activity

In related news, major shareholder Growth N. V. Biotech sold 5,784,292 shares of the firm’s stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $2.07, for a total transaction of $11,973,484.44. Following the completion of the sale, the insider now directly owns 2,733,547 shares in the company, valued at approximately $5,658,442.29. This trade represents a 67.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 8.87% of the company’s stock.

Institutional Investors Weigh In On Black Diamond Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of BDTX. Barclays PLC increased its position in Black Diamond Therapeutics by 201.9% during the third quarter. Barclays PLC now owns 78,151 shares of the company’s stock worth $339,000 after purchasing an additional 52,265 shares during the last quarter. SG Americas Securities LLC purchased a new position in Black Diamond Therapeutics during the fourth quarter worth about $42,000. Rhumbline Advisers boosted its stake in Black Diamond Therapeutics by 14.9% during the fourth quarter. Rhumbline Advisers now owns 56,135 shares of the company’s stock worth $120,000 after buying an additional 7,290 shares during the period. Bank of New York Mellon Corp boosted its stake in Black Diamond Therapeutics by 46.1% during the fourth quarter. Bank of New York Mellon Corp now owns 207,074 shares of the company’s stock worth $443,000 after buying an additional 65,341 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in Black Diamond Therapeutics during the fourth quarter worth about $53,000. 95.47% of the stock is currently owned by institutional investors and hedge funds.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.